Princess Margaret Cancer Center at University Health Network PHASE 2
Welcome,         Profile    Billing    Logout  
 0 Trials 
8 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Geoffrey
OCELOT, NCT04335292: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting
2
200
Canada
Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
Mark Vincent, AstraZeneca
Non-Small Cell Lung Cancer
06/26
06/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
NCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Recruiting
N/A
425
Canada
Breathprint analysis and patient-reported outcomes
University Health Network, Toronto, University of Amsterdam
NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer
05/24
05/24
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Liu, Geoffrey
OCELOT, NCT04335292: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge

Recruiting
2
200
Canada
Osimertinib First-Line, Platinum + Pemetrexed Chemotherapy Second-Line, Osimertinib Third-Line
Mark Vincent, AstraZeneca
Non-Small Cell Lung Cancer
06/26
06/27
ARROS-1, NCT05118789 / 2021-002477-26: A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement

Recruiting
1/2
359
Europe, Canada, Japan, US, RoW
NVL-520
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
10/25
10/26
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
EXTRACT, NCT05207423: A Chart Review Study of Adults With Advanced NSCLC

Completed
N/A
179
Europe, Canada, RoW
Takeda
Non-small Cell Lung Cancer (NSCLC)
02/23
02/23
NCT04146064: Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response

Recruiting
N/A
425
Canada
Breathprint analysis and patient-reported outcomes
University Health Network, Toronto, University of Amsterdam
NSCLC, Melanoma, Kidney Cancer, Urothelial Carcinoma, Head and Neck Cancer
05/24
05/24
CARMA-BROS, NCT04151342: CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)

Recruiting
N/A
1000
Canada
Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents., Patient-reported outcomes (PROs)
University Health Network, Toronto, Takeda Canada, Inc., Applied Health Research Centre, Programs for Assessment of Technology in Health Research Institute, AstraZeneca, Amgen, Bayer, AnHeart Therapeutics Inc.
Cancer, Malignancies Multiple, Malignant Solid Tumor, Cancer, Therapy-Related, Molecular Sequence Variation, Genetic Alteration, Gene Fusion, Receptor Tyrosine Kinase Gene Mutation, RTK Family Gene Mutation, Ras (Kras or Nras) Gene Mutation
12/25
12/25
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27

Download Options